GelSana Therapeutics
GelSana Therapeutics develops biomaterial-based wound dressings using zwitterionic polymer technology to address excessive inflammation and promote accelerated healing of chronic, surgical, and burn wounds. Founded in 2020, the company applies engineering and scientific research to produce advanced, stretchable, and moisture-managing wound care solutions designed to improve patient outcomes. Our first product CleraFlex, launched clinically in April 2026, is designed to address multiple factors in the wound healing cascade in a single drug-free product: inflammation, infection, and moisture management.
Industries
N/A
Nr. of Employees
small (1-50)
GelSana Therapeutics is currently seeking investment
GelSana Therapeutics is seeking a series-a investment in the range of 5m-20m
Products
CleraFlex Stretchable Wound and Burn Dressing
CleraFlex(TM) is a single-use, non-sterile wound dressing made from stretchable zwitterionic polymers, designed to reduce inflammation, promote healing, maintain moisture balance, and prevent bacterial adhesion. Indicated for use on chronic wounds, post-surgical wounds, second-degree burns, ulcers, pressure sores, and incisions.
CleraFlex Stretchable Wound and Burn Dressing
CleraFlex(TM) is a single-use, non-sterile wound dressing made from stretchable zwitterionic polymers, designed to reduce inflammation, promote healing, maintain moisture balance, and prevent bacterial adhesion. Indicated for use on chronic wounds, post-surgical wounds, second-degree burns, ulcers, pressure sores, and incisions.
Expertise Areas
- Biomaterials engineering
- Wound healing and inflammation modulation
- Polymer science
- Chronic and acute wound management
Key Technologies
- Zwitterionic polymer hydrogels
- Moisture-balancing wound dressings
- Anti-adhesive biomaterial surfaces
- Elastic and extrudable polymer formulations
Key People
News & Updates
Collaborators received the 2026 American Burn Association award for research evaluating zwitterionic wound dressing technology.
Founder Melissa Krebs inducted into American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
Selected winner at TechConnect World Innovation Conference Medical Innovation Challenge 2022.
Received grant as part of Colorado's Advanced Industries Accelerator Program supporting innovative technology development.
Publication describing photopolymerized anti-inflammatory hydrogels with sustained delivery capabilities in wound applications.
Study on photopolymerized zwitterionic hydrogels delivering nanoparticle conjugates for improved healing of diabetic wounds.
Collaborators received the 2026 American Burn Association award for research evaluating zwitterionic wound dressing technology.
Founder Melissa Krebs inducted into American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
Selected winner at TechConnect World Innovation Conference Medical Innovation Challenge 2022.
Received grant as part of Colorado's Advanced Industries Accelerator Program supporting innovative technology development.
Publication describing photopolymerized anti-inflammatory hydrogels with sustained delivery capabilities in wound applications.
Study on photopolymerized zwitterionic hydrogels delivering nanoparticle conjugates for improved healing of diabetic wounds.